Figure 3.

Effect of anti-Fli-1 drugs on the proliferation of human erythroleukemia cell line HEL. HEL cells (1 × 10⁴) were plated in triplicate and treated with the indicated concentrations of (a) peruvoside (Per), (b) calcimycin (Cal), (c) CPT or the vehicle control DMSO for 4 days (D1-4). The viable cells were counted on the indicated days using trypan blue exclusion assay. At 24 h post drug treatment the leukemic cells were subjected to western blot analysis using an anti-Fli-1 antibody. (d) HEL cells were treated with the indicated concentrations of peruvoside for 24 h and subjected to northern blot analysis using a fli-1 cDNA probe.